Literature DB >> 21953377

Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

Tuhina Neogi1, Jacob George, Sushma Rekhraj, Allan D Struthers, Hyon Choi, Robert A Terkeltaub.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21953377      PMCID: PMC3265683          DOI: 10.1002/art.33369

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  125 in total

1.  The mechanism of conversion of rat liver xanthine dehydrogenase from an NAD+-dependent form (type D) to an O2-dependent form (type O).

Authors:  W R Waud; K V Rajagopalan
Journal:  Arch Biochem Biophys       Date:  1976-02       Impact factor: 4.013

2.  Similar functions of uric acid and ascorbate in man?

Authors:  P Proctor
Journal:  Nature       Date:  1970-11-28       Impact factor: 49.962

3.  Hyperuricemia induces endothelial dysfunction.

Authors:  Uday M Khosla; Sergey Zharikov; Jennifer L Finch; Takahiko Nakagawa; Carlos Roncal; Wei Mu; Karina Krotova; Edward R Block; Sharma Prabhakar; Richard J Johnson
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

4.  Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.

Authors:  A D Gavin; A D Struthers
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

5.  Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.

Authors:  Katrine L Wallace; Aylin A Riedel; Nancy Joseph-Ridge; Robert Wortmann
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

6.  Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial.

Authors: 
Journal:  N Engl J Med       Date:  1978-02-09       Impact factor: 91.245

7.  Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

8.  Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?

Authors:  Niels Engberding; Stephan Spiekermann; Arnd Schaefer; André Heineke; Antje Wiencke; Maja Müller; Martin Fuchs; Denise Hilfiker-Kleiner; Burkhard Hornig; Helmut Drexler; Ulf Landmesser
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

9.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study.

Authors:  Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf De Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

Review 10.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

Authors:  Cristine E Berry; Joshua M Hare
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

View more
  16 in total

1.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

2.  Gout: multinational gout guidelines: how do we move beyond 'déjà vu'?

Authors:  Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2013-09-17       Impact factor: 20.543

3.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

Review 4.  Gout.

Authors:  Tuhina Neogi
Journal:  Ann Intern Med       Date:  2016-07-05       Impact factor: 25.391

Review 5.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

Review 6.  Urate and osteoarthritis: Evidence for a reciprocal relationship.

Authors:  Tuhina Neogi; Svetlana Krasnokutsky; Michael H Pillinger
Journal:  Joint Bone Spine       Date:  2018-11-22       Impact factor: 4.929

Review 7.  Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.

Authors:  Nicola Dalbeth; Hyon K Choi; Robert Terkeltaub
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

8.  Management of Gout and Hyperuricemia in CKD.

Authors:  Ana Beatriz Vargas-Santos; Tuhina Neogi
Journal:  Am J Kidney Dis       Date:  2017-04-26       Impact factor: 8.860

9.  Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.

Authors:  Ana Beatriz Vargas-Santos; Christine E Peloquin; Yuqing Zhang; Tuhina Neogi
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

10.  Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.

Authors:  Gerald Levy; Jiaxiao M Shi; T Craig Cheetham; Nazia Rashid
Journal:  Perm J       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.